Re: Cost-Effectiveness of Pembrolizumab in Second-Line Advanced Bladder Cancer

被引：0
|
作者：
Chang, Sam S.
机构：
来源：
JOURNAL OF UROLOGY | 2019年 / 202卷 / 06期
关键词：
D O I：
10.1097/01.JU.0000585768.72427.cb
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：1095 / 1096
页数：2
相关论文
共 50 条
  • [1] Cost-effectiveness of Pembrolizumab in Second-line Advanced Bladder Cancer
    Sarfaty, Michal
    Hall, Peter S.
    Chan, Kelvin K. W.
    Virik, Kiran
    Leshno, Moshe
    Gordon, Noa
    Moore, Assaf
    Neiman, Victoria
    Rosenbaum, Eli
    Goldstein, Daniel A.
    EUROPEAN UROLOGY, 2018, 74 (01) : 57 - 62
  • [2] Cost-effectiveness of pembrolizumab in second-line advanced bladder cancer
    Sarfaty, Michal
    Hall, Peter
    Chan, Kelvin K.
    Virik, Kiran
    Leshno, Moshe
    Gordon, Noa
    Moore, Assaf
    Neiman, Victoria
    Rosenbaum, Eli
    Goldstein, Daniel A.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (06)
  • [3] COST-EFFECTIVENESS OF PEMBROLIZUMAB AS SECOND-LINE TREATMENT FOR PATIENTS WITH ADVANCED UROTHELIAL CANCER IN FRANCE
    Robert, J.
    Culine, S.
    Roupret, M.
    Zhong, Y.
    Prabhu, V. S.
    Xu, R.
    Li, H.
    Lafuma, A.
    Bensimon, L.
    Clement, A.
    VALUE IN HEALTH, 2018, 21 : S44 - S44
  • [4] COST-EFFECTIVENESS ANALYSIS OF PEMBROLIZUMAB IN COMBINATION WITH LENVATINIB FOR THE TREATMENT OF ADVANCED SECOND-LINE ENDOMETRIAL CANCER
    Yfantopoulos, N.
    Gountas, I
    Skroumpelos, A.
    Theiakos, K.
    Economou, O.
    Karokis, A.
    VALUE IN HEALTH, 2024, 27 (12) : S113 - S113
  • [5] Cost-effectiveness of Pembrolizumab as a Second-Line Therapy for Hepatocellular Carcinoma
    Chiang, Chi-leung
    Chan, Sik-kwan
    Lee, Shing-fung
    Wong, Irene Oi-ling
    Choi, Horace Cheuk-wai
    JAMA NETWORK OPEN, 2021, 4 (01)
  • [6] Cost-Effectiveness of Capivasertib as a Second-Line Therapy for Advanced Breast Cancer
    Nguyen, Trang T. H.
    Mital, Shweta
    PHARMACOECONOMICS, 2025, 43 (03) : 351 - 361
  • [7] COST-EFFECTIVENESS ANALYSIS OF PEMBROLIZUMAB AS A SECOND-LINE THERAPY FOR ADVANCED UROTHELIAL CARCINOMA IN THE UNITED STATES
    Chen, N. C.
    McQueen, R.
    VALUE IN HEALTH, 2023, 26 (12) : S122 - S122
  • [8] Pembrolizumab as second-line therapy of hepatocellular carcinoma: A cost-effectiveness analysis
    Chan, S.
    Chiang, C.
    Lee, S.
    Wong, I.
    Choi, H.
    ANNALS OF ONCOLOGY, 2020, 31 : S174 - S174
  • [9] Cost-Effectiveness Analysis of Second-Line Chemotherapy Agents for Advanced Gastric Cancer
    Lam, Simon W.
    Wai, Maya
    Lau, Jessica E.
    McNamara, Michael
    Earl, Marc
    Udeh, Belinda
    PHARMACOTHERAPY, 2017, 37 (01): : 94 - 103
  • [10] Cost-effectiveness of Pembrolizumab as Second-line Therapy for the Treatment of Locally Advanced or Metastatic Urothelial Carcinoma in Sweden
    Srivastava, Tushar
    Prabhu, Vimalanand S.
    Li, Haojie
    Xu, Ruifeng
    Zarabi, Natalie
    Zhong, Yichen
    Pellissier, James M.
    Perini, Rodolfo F.
    de Wit, Ronald
    Mamtani, Ronac
    EUROPEAN UROLOGY ONCOLOGY, 2020, 3 (05): : 663 - 670
12345